Premium
Anticancer Activity of Half‐Sandwich Rh III and Ir III Metalla‐Prisms Containing Lipophilic Side Chains
Author(s) -
Gupta Gajendra,
Mahesh Kumar Jerald,
Garci Amine,
Rangaraj Nandini,
Nagesh Narayana,
Therrien Bruno
Publication year - 2014
Publication title -
chempluschem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.801
H-Index - 61
ISSN - 2192-6506
DOI - 10.1002/cplu.201300425
Subject(s) - chemistry , rhodium , iridium , trifluoromethanesulfonate , cationic polymerization , in vitro , stereochemistry , medicinal chemistry , in vivo , derivative (finance) , polymer chemistry , catalysis , organic chemistry , biochemistry , microbiology and biotechnology , financial economics , economics , biology
Two hexacationic pentamethylcyclopentadienyl rhodium(III) and iridium(III) metalla‐prisms, [(η 5 ‐C 5 Me 5 ) 6 M 6 (μ 3 ‐tpt‐κ N ) 2 (μ 4 ‐C 6 HRO 4 ‐κ O ) 3 ] 6+ (tpt=2,4,6‐tri‐(pyridin‐4‐yl)‐1,3,5‐triazine; R=(CH 2 ) 10 CH 3 ; M=Rh, [ 3 ] 6+ ; M=Ir, [ 4 ] 6+ ) isolated as their triflate salts, have been synthesised from the dinuclear complexes (η 5 ‐C 5 Me 5 ) 2 M 2 (μ 4 ‐C 6 HRO 4 ‐κ O )Cl 2 (M=Rh, 1 ; M=Ir, 2 ) and AgCF 3 SO 3 . The antiproliferative activity of the neutral and cationic complexes has been evaluated in vitro in human cancer cell lines. The positively charged metalla‐prisms appear to target mitochondria, which ultimately induce apoptosis in cancer cells. All biological studies suggest that the rhodium derivative [ 3 ][CF 3 SO 3 ] 6 possesses excellent activities, not only in vitro but also in vivo in tumour‐induced C57L6/J mice.